A Late Dermatologic Presentation of Bullous Pemphigoid Induced by Anti-PD-1 Therapy and Associated with Unexplained Neurological Disorder.
Anti-PD-1 antibody
Anti-PD-L1 antibody
Bullous pemphigoid
Immunotherapy
Melanoma
Neurological disorder
Journal
Case reports in oncology
ISSN: 1662-6575
Titre abrégé: Case Rep Oncol
Pays: Switzerland
ID NLM: 101517601
Informations de publication
Date de publication:
Historique:
received:
22
01
2021
accepted:
22
01
2021
entrez:
12
7
2021
pubmed:
13
7
2021
medline:
13
7
2021
Statut:
epublish
Résumé
Immunotherapy has become the standard of care for various cancer types. The widespread use of immune checkpoints inhibitors confronts us with a whole range of novel immune-related adverse events. Skin toxicity is one of the most frequent adverse events. In this article, we report a case of anti-PD-1 induced late bullous pemphigoid (BP) with mucosal erosions and associated with a troublesome neurological disorder of undetermined origin in a patient with metastatic melanoma. Skin biopsy was essential to make the diagnosis and rapid initiation of systemic prednisolone played a role in favorable clinical outcome of BP. We will discuss the difficulty of early diagnosis of BP, its unusual association with neurological disorders, and the specific management of this particular dermatological entity.
Identifiants
pubmed: 34248552
doi: 10.1159/000514806
pii: cro-0014-0861
pmc: PMC8255709
doi:
Types de publication
Case Reports
Langues
eng
Pagination
861-867Informations de copyright
Copyright © 2021 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to declare.
Références
J Cutan Pathol. 2016 Sep;43(9):787-91
pubmed: 27161449
Int J Dermatol. 2018 Jun;57(6):664-669
pubmed: 29630716
Br J Dermatol. 2015 Apr;172(4):867-77
pubmed: 25827742
J Clin Oncol. 2018 Jun 10;36(17):1714-1768
pubmed: 29442540
Melanoma Res. 2016 Aug;26(4):413-6
pubmed: 27031539
Australas J Dermatol. 2017 Aug;58(3):e109-e112
pubmed: 27170423
J Dermatol. 2018 Jan;45(1):e21-e22
pubmed: 28944534
Sci Rep. 2016 Nov 15;6:37125
pubmed: 27845416
J Am Acad Dermatol. 2018 Dec;79(6):1081-1088
pubmed: 30025829
JRSM Open. 2018 Oct 03;9(10):2054270418793029
pubmed: 30302265
Histochem Cell Biol. 2012 Oct;138(4):653-67
pubmed: 22688676
Br J Dermatol. 2018 Oct;179(4):993-994
pubmed: 29758087
JAMA Dermatol. 2019 Feb 1;155(2):166-171
pubmed: 30624571
Am J Clin Dermatol. 2018 Jun;19(3):345-361
pubmed: 29256113
J Immunother. 2018 Apr;41(3):164-167
pubmed: 29309291
Front Med (Lausanne). 2018 Sep 27;5:268
pubmed: 30320114
An Bras Dermatol. 2015 Mar-Apr;90(2):280-2
pubmed: 25831008
Oncologist. 2018 Oct;23(10):1119-1126
pubmed: 30018132
Asia Pac J Oncol Nurs. 2017 Apr-Jun;4(2):127-135
pubmed: 28503645
J Dermatol. 2019 Dec;46(12):1102-1135
pubmed: 31646663
JAAD Case Rep. 2019 Oct 03;5(10):898-903
pubmed: 31646161
Cancers (Basel). 2020 Mar 20;12(3):
pubmed: 32245016
Eur J Dermatol. 2019 Oct 1;29(5):552-554
pubmed: 31570326
Eur J Dermatol. 2017 Oct 1;27(5):472-481
pubmed: 28681724